VTE is persistent

The unmet need is well-defined

VTE risk is highest in the first 30 days, starting with hospital admission1

Cumulative risk of VTE in hospitalized acutely ill medical patients
through 180 days post-admission (N=11,139)1

Mean Hospital Stay: 5.3 (±5.3) Days Greatest VTE Risk: Days 0-30 52.6% of cumulative 6-month VTE risk occurs by day 30 100 80 60 40 20 0 20 40 60 80 100 120 140 160 180 0.000 0.007 0.014 0.021 0.028 0.035 6 9 12 17 23 41 56 95 120 180 DAYS AFTER INITIAL HOSPITALIZATION 180-DAYS CUMULATIVE PROBABILITY (%) CUMULATIVE PROBABILITY OF VTE
52.6% of cumulative 6-mo VTE risk occurs by day 30
VTE Webnar

Register for the webinar*
Venous Thromboembolism: Pervasive, Persistent, Preventable

First in a series of live peer-to-peer webinars about the unmet need for VTE prophylaxis in acutely ill medical patients after hospital discharge.

*For US health care professionals only.

See the full scope of this deadly
yet preventable problem2,3

For hospitalized acutely ill medical patients

Until recently, there was no approved anticoagulant for extended-duration VTE prophylaxis, because past clinical trials failed to show net clinical benefits in this setting4-6

6 Rivaroxaban MAGELLAN (N=8101; vs enoxaparin) 5 Apixaban ADOPT (N=6528; vs enoxaparin) 4 Enoxaparin EXCLAIM (N=6085; vs placebo) Incidence (%) Major Bleeding VTE Events Increased Bleeding Increased Bleeding Increased Bleeding Reduced VTE No Difference in VTE Reduced VTE -1.3% ( P =0.02) -0.4% ( P =0.44) -1.5% ( P <0.04) +0.7% ( P <0.001) +0.3% ( P =0.04) +0.5% ( P <0.05)
VTE reduction rate vs bleeding risk in Phase III VTE prophylaxis trials
Up to 80% of fatal VTEs occur in acutely ill medical patients

of fatal VTE events occur in acutely ill medical patients8

Huang et al, 2015

The unmet medical need

There is a need for extended-duration VTE prophylaxis that provides…

VTE Newsletter Signup

Register for updates*

Concerned about your acutely ill medical patients and VTE?
Sign up to receive updates and access to new resources as they become available.

*For US health care professionals only.

  1. Amin AN, Varker H, Princic N, Lin J, Thompson S, Johnston S. Duration of venous thromboembolism risk across a continuum in medically ill hospitalized patients. J Hosp Med. 2012;7(3):231-238.
  2. Futterman LG, Lemberg L. A silent killer—often preventable. Am J Crit Care. 2004;13(5):431-436.
  3. Korjian S, Daaboul Y, Halaby R, et al. Extended-duration thromboprophylaxis among acute medically ill patients: an unmet need. J Cardiovasc Pharmacol Ther. 2016;21(3):227-232.
  4. Hull RD, Schellong SM, Tapson VF, et al. Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial. Ann Int Med. 2010;153(1):8-18.
  5. Goldhaber SZ, Leizorovicz A, Kakkar AK, et al; the ADOPT Trial Investigators. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. N Engl J Med. 2011;365(23):2167-2177.
  6. Cohen AT, Spiro TE, Büller HR, et al; the MAGELLAN Investigators. Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N Engl J Med. 2013;368(6):513-523.
  7. Khan SR, Lim W, Dunn AS, et al. Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 suppl):e195S-e226S.
  8. Huang W, Anderson FA, Rushton-Smith SK, Cohen AT. Impact of thromboprophylaxis across the US acute care setting. PLoS ONE. 2015;10(3): e0121429.
  9. Anderson FA, Zayaruzny M, Heit JA, Fidan D, Cohen AT. Estimated annual numbers of US acute-care hospital patients at risk for venous thromboembolism. Am J Hematol. 2007;82(9):777-782.

Worried about VTE risk?  Learn About A Treatment Option

Okay Okay Okay Okay Okay  Cancel